BR112017010645A2 - derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos - Google Patents

derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos

Info

Publication number
BR112017010645A2
BR112017010645A2 BR112017010645A BR112017010645A BR112017010645A2 BR 112017010645 A2 BR112017010645 A2 BR 112017010645A2 BR 112017010645 A BR112017010645 A BR 112017010645A BR 112017010645 A BR112017010645 A BR 112017010645A BR 112017010645 A2 BR112017010645 A2 BR 112017010645A2
Authority
BR
Brazil
Prior art keywords
preparation
derivatives
pyridinecarboxamide
pyridinecarboxamide derivatives
pharmaceutical uses
Prior art date
Application number
BR112017010645A
Other languages
English (en)
Inventor
Sun Piaoyang
Dong Qing
Li Xin
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of BR112017010645A2 publication Critical patent/BR112017010645A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção se refere a derivados da piridinacarboxamida, a um método para a preparação dos mesmos, e a um uso farmacêutico dos mesmos. especificamente, presente invenção se refere a derivados da piridinacarboxamida representados pela fórmula geral (i), em que os substituintes da fórmula (i) são definidos como os mesmos conforme na especificação, a um método para a preparação para os mesmos, a uma composição farmacêutica que compreende os derivados, e aos usos como agentes terapêuticos, especialmente como inibidores do canal de potássio modular externo renal (romk) e para a preparação de medicamentos para o tratamento e/ou a prevenção de hipertensão e insuficiência cardíaca.
BR112017010645A 2014-12-08 2015-11-10 derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos BR112017010645A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410741280 2014-12-08
PCT/CN2015/094164 WO2016091042A1 (zh) 2014-12-08 2015-11-10 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
BR112017010645A2 true BR112017010645A2 (pt) 2017-12-26

Family

ID=56106663

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017010645A BR112017010645A2 (pt) 2014-12-08 2015-11-10 derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos

Country Status (12)

Country Link
US (3) US10364234B2 (pt)
EP (1) EP3231802B1 (pt)
JP (1) JP6736816B2 (pt)
KR (1) KR20170090477A (pt)
CN (1) CN105980379B (pt)
AU (1) AU2015361614B2 (pt)
BR (1) BR112017010645A2 (pt)
CA (1) CA2966788A1 (pt)
MX (2) MX2017006536A (pt)
RU (1) RU2694899C9 (pt)
TW (1) TWI718113B (pt)
WO (1) WO2016091042A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2962315T3 (es) 2016-04-20 2024-03-18 Bristol Myers Squibb Co Compuestos heterocíclicos bicíclicos sustituidos
CA3024727A1 (en) * 2016-06-07 2017-12-14 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor
CN106432071B (zh) * 2016-09-05 2019-04-02 河北正朗制药有限公司 5-氰基-4-甲氧基-2-吡啶甲酸的盐酸盐的制备及其应用
MX2019004999A (es) 2016-11-03 2019-08-05 Squibb Bristol Myers Co Derivados biciclo hetorociclicos sustituidos, utiles como inhibidores del canal de potasio medular externo renal (romk).
CN108113988A (zh) * 2016-11-29 2018-06-05 江苏恒瑞医药股份有限公司 一种romk抑制剂与arb联合在制备治疗和/或预防高血压或心力衰竭的药物中的用途
EP3929194B1 (en) 2017-06-01 2024-04-17 Bristol-Myers Squibb Company Substituted nitrogen containing compounds
CN109983008A (zh) * 2017-07-10 2019-07-05 江苏恒瑞医药股份有限公司 一种吡啶甲酰胺类衍生物的制备方法及其中间体
CN109879863B (zh) * 2017-12-06 2020-10-20 江苏恒瑞医药股份有限公司 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法
WO2019109935A1 (zh) * 2017-12-06 2019-06-13 江苏恒瑞医药股份有限公司 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法
WO2020173476A1 (zh) * 2019-02-28 2020-09-03 江苏恒瑞医药股份有限公司 一种含有肾脏钾离子外排通道抑制剂的药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2231600B1 (en) * 2007-11-16 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
US8673920B2 (en) * 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2012058116A1 (en) 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2632464B1 (en) 2010-10-29 2015-04-29 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
KR20140052034A (ko) * 2011-08-19 2014-05-02 머크 샤프 앤드 돔 코포레이션 신장 외수질 칼륨 채널의 억제제
WO2013039802A1 (en) 2011-09-16 2013-03-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999990B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
AR092031A1 (es) * 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
WO2014015495A1 (en) 2012-07-26 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9777002B2 (en) * 2012-11-29 2017-10-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel

Also Published As

Publication number Publication date
CN105980379A (zh) 2016-09-28
US10759788B2 (en) 2020-09-01
RU2017121460A (ru) 2019-01-10
AU2015361614A1 (en) 2017-06-22
RU2694899C2 (ru) 2019-07-18
JP6736816B2 (ja) 2020-08-05
US10442794B2 (en) 2019-10-15
WO2016091042A1 (zh) 2016-06-16
MX2017006536A (es) 2017-08-09
EP3231802A4 (en) 2018-05-02
RU2694899C9 (ru) 2019-08-28
JP2017536383A (ja) 2017-12-07
US20190152959A1 (en) 2019-05-23
TWI718113B (zh) 2021-02-11
AU2015361614B2 (en) 2019-11-28
US20190152958A1 (en) 2019-05-23
US20170342059A1 (en) 2017-11-30
KR20170090477A (ko) 2017-08-07
RU2017121460A3 (pt) 2019-03-28
EP3231802B1 (en) 2021-05-05
TW201620898A (zh) 2016-06-16
MX2020011818A (es) 2021-01-15
US10364234B2 (en) 2019-07-30
CN105980379B (zh) 2018-09-07
CA2966788A1 (en) 2016-06-16
EP3231802A1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
BR112017010645A2 (pt) derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
BR112019003557A2 (pt) derivados de oxopicolinamida, método de preparação dos mesmos e uso farmacêutico dos mesmos
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
TN2017000529A1 (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2017016376A (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112017026132A2 (pt) piridinas substituídas e métodos de uso
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112018005932A2 (pt) inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
BR112018011817A2 (pt) derivado de benzopiperidina, método de preparação do mesmo, e uso médico do mesmo
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
TW201613885A (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112017006085A2 (pt) compostos 1-alquil-6-oxo-1,6-di-hidropiridin-3-ila e uso como moduladores sgrm
CL2018000363A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana.
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112018070363A2 (pt) derivados de tetraidroisoquinolina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2696 DE 06-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.